$BMY sends $PFE $TAK Adcetris a shot across the bows. Via @ApexOnco -> https://t.co/JW2jzGpKHf

Hands up who before yesterday had heard of the SWOG S1826 study... 8 Apr 2026 Pdufa date for $BMY Opdivo + chemo in 1L Hodgkin's where it beat $PFE $TAK Adcetris: 3yr PFS FU via Alex Herrera @ #ASH25 https://t.co/gKPGs5tTOx
$IVBXF perseveres with IL-2 cytokine and scores a big deal at last. Some disappointment that this is with $TAK and not a big pharma player? Via @ApexOnco -> https://t.co/U7G0JxKSkn
Pretty amazing run-up by $IVBXF - +135% YTD or +40% since #ASCO25 on the back of IBI363. Does today's $1.2bn up front from $TAK justify the enthusiasm?
It's cellexit! $TAK
@jq1234t @ByMadeleineA And guess what the carrying value of $TAK Gammadelta was (not sure the acquisition price had ever been disclosed) https://t.co/ESUJMzrJQC
So apparently it's all over for $TAK in cell therapy https://t.co/fVcLcSn0gG https://t.co/Sv24FmgVZ6
My earlier take on this and other ADCs that use Sting agonist payloads, from July: https://t.co/B879yVppH0 $DSNKY $ESALY $EXEL $MKGAF $TAK $MRSN $GSK
$ALKS $TAK orexin data presentations from the sleep meeting in Singapore. Alkermes, Takeda show encouraging data on narcolepsy drugs https://t.co/TJtEk9EgeB via @elaineywchen